MX2016000393A - Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. - Google Patents

Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.

Info

Publication number
MX2016000393A
MX2016000393A MX2016000393A MX2016000393A MX2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A MX 2016000393 A MX2016000393 A MX 2016000393A
Authority
MX
Mexico
Prior art keywords
lysine
microbial transglutaminase
protein modifications
chemoenzymatic
specific
Prior art date
Application number
MX2016000393A
Other languages
English (en)
Spanish (es)
Inventor
Usera Aimee
ROBINSON Zachary
cobb Jennifer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016000393A publication Critical patent/MX2016000393A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
    • C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016000393A 2013-07-11 2014-07-11 Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. MX2016000393A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845273P 2013-07-11 2013-07-11
US201462016044P 2014-06-23 2014-06-23
PCT/US2014/046409 WO2015006728A2 (en) 2013-07-11 2014-07-11 Site-specific chemoenzymatic protein modifications

Publications (1)

Publication Number Publication Date
MX2016000393A true MX2016000393A (es) 2016-10-26

Family

ID=51298955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000393A MX2016000393A (es) 2013-07-11 2014-07-11 Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.

Country Status (12)

Country Link
US (4) US9359400B2 (enExample)
EP (2) EP3613755A1 (enExample)
JP (1) JP6739333B2 (enExample)
KR (1) KR20160040556A (enExample)
CN (1) CN105593238B (enExample)
AU (1) AU2014286990A1 (enExample)
BR (1) BR112016000585A2 (enExample)
CA (1) CA2918076A1 (enExample)
EA (1) EA201690205A1 (enExample)
ES (1) ES2756526T3 (enExample)
MX (1) MX2016000393A (enExample)
WO (1) WO2015006728A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP4032902A1 (en) 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
SG11201810470XA (en) 2016-06-10 2018-12-28 Eisai R&D Man Co Ltd Lysine conjugated immunoglobulins
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
EP3691677A4 (en) 2017-10-04 2021-07-07 Pogona, Llc COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
US12344598B2 (en) * 2019-01-25 2025-07-01 Avedro, Inc. Bis(diazirine) derivatives as photo-crosslinker for treating corneal ectatic disorders
JP2025520445A (ja) * 2022-06-16 2025-07-03 ザ ジェネラル ホスピタル コーポレイション 細胞イメージング用のビシクロノニン試薬
CN119375471A (zh) * 2023-07-26 2025-01-28 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
DE4022267C2 (de) 1990-07-12 1994-09-15 Degussa N-Acyldipeptide und deren Verwendung
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2142981C (en) 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5508191A (en) 1993-07-05 1996-04-16 Takeda Chemical Industries, Ltd. Mutant strains of agrobacterium for producing β-1,3-glucan
EP0777726B1 (en) 1994-08-26 2006-06-07 Novozymes A/S Microbial transglutaminases, their production and use
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
ATE248219T1 (de) 1995-01-19 2003-09-15 Novozymes As Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
EP0815833B1 (en) 1996-06-24 2003-04-09 Givaudan SA Malodour preventing agents
US6620916B1 (en) 1996-09-26 2003-09-16 Ajinomoto Co., Inc. Modified physiologically active proteins and medicinal compositions containing the same
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
JP3981525B2 (ja) 1998-01-20 2007-09-26 ハワード・グリーン 組織への物質のトランスグルタミナーゼ連結
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
US7605175B2 (en) 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2006028129A1 (ja) 2004-09-10 2006-03-16 Toray Industries, Inc. 医薬品製剤
MX2007005202A (es) 2004-11-01 2007-07-09 Brigham & Womens Hospital Polisacaridos de estreptococo modificados y usos de los mismos.
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
BRPI0611570A2 (pt) * 2005-06-15 2011-02-22 Novo Nordisk Healthcare Ag métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5703020B2 (ja) * 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
US8426179B2 (en) * 2007-08-30 2013-04-23 Northwestern University Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme
DE102007044296A1 (de) * 2007-09-17 2009-03-19 Hans-Lothar Prof. Dr. Fuchsbauer Strukturmodulator von Proteinen
US8137925B2 (en) * 2007-11-09 2012-03-20 Massachusetts Institute Of Technology Methods and compositions for protein labeling using lipoic acid ligases
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US20110184147A1 (en) * 2008-07-04 2011-07-28 Kyushu University, National University Corporation Enzyme substrate for labeling of protein
US20110306551A1 (en) * 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US8853151B2 (en) 2009-06-30 2014-10-07 The Regents Of The University Of Michigan Pro-drug complexes and related methods of use
US20110020837A1 (en) 2009-07-07 2011-01-27 Universiteit Utrecht Holding B.V. Method for isolating or identifying a target protein interacting with a lipid in a cell
EP2515914A4 (en) 2009-12-23 2013-09-11 Scripps Research Inst BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
US8859629B2 (en) * 2010-04-27 2014-10-14 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130178609A1 (en) 2010-07-09 2013-07-11 Centre National De La Recherche Scientifique - Cnrs Modular construction of lipophospholipids
CN103298949A (zh) 2010-10-29 2013-09-11 生命科技公司 生物素衍生物
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
EP2651411B1 (en) 2010-12-13 2020-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
FR2981352B1 (fr) 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
CN104145015A (zh) * 2011-12-01 2014-11-12 安吉奥开米公司 靶向的溶酶体酶化合物
JP5509440B2 (ja) * 2012-06-22 2014-06-04 国立大学法人九州大学 タンパク質−核酸複合体の製造方法および標的物の検出方法
KR20160042871A (ko) * 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
KR20160040556A (ko) * 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형

Also Published As

Publication number Publication date
CN105593238B (zh) 2020-09-08
US9359400B2 (en) 2016-06-07
JP2016526574A (ja) 2016-09-05
JP6739333B2 (ja) 2020-08-12
EP3613755A1 (en) 2020-02-26
BR112016000585A2 (pt) 2018-03-20
WO2015006728A3 (en) 2015-03-12
EP3019515A2 (en) 2016-05-18
US20190300570A1 (en) 2019-10-03
EP3019515B1 (en) 2019-08-21
CA2918076A1 (en) 2015-01-15
KR20160040556A (ko) 2016-04-14
US20160237116A1 (en) 2016-08-18
WO2015006728A2 (en) 2015-01-15
US20220089639A1 (en) 2022-03-24
CN105593238A (zh) 2016-05-18
ES2756526T3 (es) 2020-04-27
US10975120B2 (en) 2021-04-13
US20150017192A1 (en) 2015-01-15
AU2014286990A1 (en) 2016-02-11
EA201690205A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
WO2015006728A3 (en) Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
TN2012000167A1 (en) Human il-23 antigen binding proteins
PH12015501651A1 (en) Antibody constructs for cdh19 and cd3
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
AR092818A1 (es) Anticuerpo tau humanizado
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
MY186864A (en) Fusion immunomodulatory proteins and methods for making same
MX2016008099A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
EA201492101A1 (ru) Антитела против fcrn
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX355041B (es) Dominios de union a albumina consenso no naturales.
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
IN2015DN01404A (enExample)
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
MX350445B (es) Analogos del factor b del complemento y sus usos.
PH12015501687A1 (en) Novel binding proteins from pcsk9
NZ766005A (en) Factor h binding protein variants and methods of use thereof
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
PH12018501443A1 (en) Methods of administering hepcidin
MX2013007872A (es) Proteina de fusion anticancer.
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.